检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
出 处:《齐齐哈尔医学院学报》2015年第6期851-852,共2页Journal of Qiqihar Medical University
摘 要:目的探讨盐酸法舒地尔注射液治疗短暂性脑缺血发作的临床疗效和安全性。方法短暂性脑缺血发作患者123例,随机分为治疗组62例和对照组61例;治疗组用盐酸法舒地尔注射液30 mg加入0.9%氯化钠注射液250 ml静脉滴注,1次/日,共7天;对照组用0.9%氯化钠注射液250 ml静脉滴注,1次/日,共7天;两组均予阿司匹林、阿托他汀等常规治疗。治疗前、治疗后分别检查全血粘度、血浆粘度和红细胞聚集。结果治疗组总有效率96.77%,对照组总有效率88.52%,两组总有效率有统计学意义(P<0.05)。治疗后,治疗组全血粘度、血浆粘度和红细胞聚集明显降低,与对照组比较有统计学意义(P<0.05)。结论盐酸法舒地尔对刺激神经功能的恢复,改善局限性脑功能缺失临床症状,有很好疗效。Objective To investigate the efficacy and safety of Fasudil hydrochloride injection in the treament of transient ischemic attack. Methods 123 patients with transient ischemic attack were randomly divided into two groups. 62 cases of the treatment group received intravenous drips of Fasudil hydrochloride injection: 30 mg of asudil hydrochloride Injection + 250ml of 0.9% Sodium Chloride Injection 1 time / day for 7 days, while 61 cases of the control group received intravenous drip of 250ml of Sodium Chloride Injection 1 time / day for 7 days. Both groups were given conventional treatment such as aspirin, atorvastatin, to observe blood viscosity, plasma viscosity and erythrocyte aggregation before and after the treatment respectively. Results The total effective rate of the control group was 96.77%, significantly higher than 88.52% of the control group, and the difference was statistically significant ( P 〈 0. 05 ). After the treatment, the whole blood viscosity, plasma viscosity and erythrocyte aggregation were significantly lower in the treatment group than those in the control group, which was statistically significant (P 〈 0. 05 ). Conclusions Fasudil hydrochloride Injection has a very good curative effect on stimulating the recovery of nerve function and improving deficiency of brain function.
关 键 词:盐酸法舒地尔注射液 短暂性脑缺血发作 临床疗效 安全性
分 类 号:R541.4[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.15